CClinicalTrials.gg
Status unknownNCT01785797Updated Feb 7, 2013

The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study

A Phase 3 interventional study of Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma in Chronic Subdural Hematoma and Subdural Drain, sponsored by Kwong Wah Hospital. Status unknown at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2013-02-07.

Sponsored by Kwong Wah Hospital · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2013), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This is a prospective randomised-controlled multi-centre trial based in Hong Kong to determine whether temporary subdural drain placement after burr hole evacuation of a chronic subdural haematoma can reduce the risk of recurrence. Consecutive patients, 60 years old or above, diagnosed to have symptomatic chronic subdural haematoma and indicated for burr hole operative drainage will be randomly allocated into one of two groups: (1) for intra-operative subdural drain placement (intervention group) or (2) not for drain placement (control group). Using web-based software block randomisation with an allocation ratio of 1:1 will be conducted. Instructions to use or not to use a drain will be contained in a sealed envelopes labelled with sequential study numbers.

Intra-operatively, if the surgeon-in-charge judges that after burr hole evacuation of the haematoma the patient's condition is unsafe for drain placement, the subject will be excluded from the study. Otherwise, randomisation will be performed at this juncture by the opening of the sealed envelop. The procedure involves placing a prefabricated silicon drain into the subdural space according to a standard protocol and will be removed on the second post-operative day at the bedside. Subjects in whom the operating surgeon judges that drain placement is unsafe will be excluded from the study. Drainage is undertaken passively by hanging the collection bag at the bedside in a dependent position. In addition to general demographic, clinical and radiological presentation data, potential risk factors for recurrence will be documented. Serial computed tomography brain scans will be arranged (before discharge, at four weeks and six months) and the occurence of significant subdural haematoma recurrence requiring repeat operative drainage at six months will be recorded. Other outcome measures to be determined at regular time intervals for a total follow-up period of six months (upon discharge, at four weeks and six months) include: functional performance in terms of the extended Glasgow Outcome Scale and modified Rankin Scale, added neurological deficit, death and other surgery-related complications. All outcomes will be documented by the trial investigators or by the responsible clinician. The data obtained will be analysed according to the principle of intention to treat.

Hypothesis: compared to burr-hole evacuation of chronic subdural haematoma alone (control), the additional placement of a subdural drain after evacuation (intervention) will reduce the risk of recurrence requiring repeat surgery.

02

Conditions studied

  • Chronic Subdural Hematoma
  • Subdural Drain
03

In context

Hematoma, Subdural

99 studies on the registry are indexed under Hematoma, Subdural; 29 are open to participants now.

This study's planned enrollment of 260 is above the median of 100 across 73 interventional studies indexed under Hematoma, Subdural.

Browse Hematoma, Subdural studies →

Lead sponsor

Kwong Wah Hospital is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients diagnosed to have symptomatic chronic subdural haematoma confirmed by a computed tomography or magnetic resonance imaging brain scan.
  2. Ethnic Chinese
  3. Age >/= 60 years-old
  4. Reasonable expectation of completion of outcome measures at follow-up
  5. Written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Unsalvageable patients: fixed and dilated pupils after resuscitation or signs of brainstem herniation that precludes definitive therapy.
  2. When the operating surgeon judges that drain placement may be hazardous or to be of limited benefit e.g. readily expanded brain in young patients.
  3. History of previous cranial neurosurgical procedure.
  4. On concurrent glucocorticoid therapy.
  5. Suspected intracranial hypotension syndrome.
  6. Blood dyscrasia:

    1. Use of antiplatelet medication e.g. aspirin or warfarin without adequate reversal or observation for drug effect to wear off (at least 5-7 days).
    2. Thrombocytopenia: platelet level \<100 x 109/l
    3. Coagulopathy: prothrombin time PT >12sec or, activated partial thromboplastin time (APTT) >37.4 sec
  7. End-stage renal/ hepatic failure.
  8. Known or strong suspicion of alcohol or illicit drug abuse.
  9. Pregnancy
  10. Known epilepsy
  11. Any neurological or non-neurological condition independent from SAH that might influence the functional outcome or other efficacy outcome measures
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • No intervention
    Control: burr hole drainage only

    Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.

  • Experimental
    Intervention: silicon subdural drain

    Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.

    Device: Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma

Interventions

  • DeviceSilicon subdural drain placement after burr hole evacuation of chronic subdural hematoma
06

What researchers measure

Primary outcomes

  1. Significant recurrent chronic subdural hematoma i.e. requiring repeat operative drainage at six months after the primary operation

    Time frame: Six months after primary burr hole evacuation of chronic subdural hematoma

Secondary outcomes

  1. 1. Functional performance in terms of the Extended Glasgow Outcome Scale

    Time frame: Upon discharge, 4 weeks and 6 months after primary operation

  2. Added neurological deficit

    Time frame: Upon discharge, at 4 weeks and 6 months after primary operation

  3. Surgery-related complications

    Time frame: Upon discharge, at 4 weeks and 6 months after primary operation

  4. Death

    Time frame: Upon discharge, at 4 weeks and 6 months after primary operation

  5. Modified Rankin Score

    Time frame: Upon discharge, at 4 weeks and 6 months

07

Study locations

1 site
  • Prince of Wales Hospital
    Hong Kong, Hong Kong, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01785797
Lead sponsor
Kwong Wah Hospital
Responsible party
Peter Woo Yat Ming (Associate Consultant, Kwong Wah Hospital) — Principal investigator
First posted
Feb 7, 2013
Start date
Jun 2013
Primary completion
Jun 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Feb 7, 2013

Study contacts

Peter YM Woo, FRCS (SN)
Contact
peterymwoo@gmail.com
852+ 3517 2275 ext. 2275

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion